Pineal Region Glioblastoma, a Case Report and Literature Review

Hayley Beacher Stowe1, C. Ryan Miller2, Jing Wu3, Dina M. Randazzo4 and Andrew Wenhua Ju1*

1 Department of Radiation Oncology, Brody School of Medicine, Greenville, NC, United States, 2 Department of Pathology, University of North Carolina School of Medicine, Chapel Hill, NC, United States, 3 Center for Cancer Research National Cancer Institute, Bethesda, MD, United States, 4 Department of Neuro-Oncology, Duke Health, Durham, NC, United States

Introduction: Pineal region glioblastoma multiforme (GBM) is a rare disease entity with a generally poor prognosis. We present a case of a patient with an unresectable pineal region GBM treated with chemoradiation with favorable outcome.

Case background: A 65-year-old patient who was presented with visual symptoms was found to have a pineal region tumor on imaging. A stereotactic biopsy showed a World Health Organization Grade IV GBM, O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylated, isocitrate dehydrogenase 1 and 2 wild type. The patient was treated with radiotherapy with concurrent temozolomide, followed by adjuvant temozolomide. Disease progression occurred at 58 weeks post-biopsy, which prompted the initiation of bevacizumab. The patient was alive and functioning well as of his last follow up, 166 weeks from the initial biopsy.

Discussion: On our review of the literature, 24 cases of pineal region GBM have been reported. The median reported survival for these previously reported cases was 6 months (range, 2–24 months). This patient has the longest overall survival reported to date for a patient with this diagnosis. This is the first patient in the literature with pineal region GBM who has been reported to have MGMT promoter methylation.

Concluding remarks: Although pineal region GBM is a rare disease entity with a generally poor prognosis, long-term survival is achievable for select patients. MGMT promoter methylation may potentially have prognostic value. Favorable control of recurrent disease with the use of bevacizumab is possible.

Keywords: pineal, glioblastoma, radiotherapy, temozolomide, O-6-methylguanine-DNA methyltransferase, bevacizumab

INTRODUCTION

Various tumor histologies can arise in the pineal region, including parenchymal tumors, neuroectodermal tumors, germ cell tumors, and meningeal tumors (1). Gliomas in the pineal region include fibrillary astrocytoma, pilocytic astrocytoma, anaplastic astrocytoma, glioblastoma, oligodendroglioma, ependymoma, and choroid plexus papilloma (2). Glioblastoma multiforme (GBM) is rarely found in the pineal region. This paper presents a case of primary GBM in the pineal region and discusses the clinical course, radiological findings, and treatment approaches with a review

Abbreviations: GBM, glioblastoma multiforme; IMRT, intensity-modulated radiation therapy; MGMT, O-6-methylguanine-DNA methyltransferase; IDH, isocitrate dehydrogenase, WHO, World Health Organization.
of the relevant literature. The patient provided written informed consent for his personal information to be used for research and publication.

CASE BACKGROUND

A 64-year-old male with no significant past medical history presented with vertical diplopia, headaches for 3 weeks, and 6 months of insomnia. His neurological examination revealed a right cranial nerve IV palsy and gait difficulties. Subsequent CT imaging, 1 month after initial presentation, revealed a poorly marginated, hyperdense mass located in the pineal region. A CT of the chest, abdomen, and pelvis, and an MRI of the total spine showed no evidence of metastatic disease. MRI of the brain revealed a heterogeneously enhancing pineal mass measuring 2.3 cm × 2.5 cm × 2.3 cm (Figure 1). The lesion was deemed unresectable due to its location and an image-guided stereotactic needle biopsy was performed. The pathology revealed a high-grade glioma composed of markedly atypical cells, many with giant nuclei and containing abundant mitotic activity (seven mitoses in three high-powered fields), multiple foci of microvascular proliferation, and areas of pseudopalisading necrosis, consistent with GBM, World Health Organization Grade IV (Figure 2). The tumor was positive for O-6-methylguanine-DNA methyltransferase (MGMT) methylation and negative for isocitrate dehydrogenase 1/2 mutations. The patient’s GBM was treated with concurrent chemoradiation followed by adjuvant chemotherapy (3, 4). The patient received intensity-modulated radiation therapy consisting of 60 Gy in 2 Gy daily fractions with concurrent temozolomide at 75 mg/m². The initial fields were treated to a dose of 50 Gy and encompassed a 2 cm margin along white matter tracts from the enhancing tumor and the surrounding edema, and also covered the third and fourth ventricles, lateral ventricles, cerebral aqueduct, tectum, partial thalamus, and partial brainstem in the clinical target volume. The majority of the lateral ventricles were covered but the extreme ends of the horns were excluded due to concerns of additional toxicity, given the volume of brain treated, the prepontine cistern was not specifically targeted. An effort was made to cover the majority of the ventricles based on prior clinical reports describing a propensity for leptomeningeal spread of disease for pineal region GBMs. This initial radiotherapy plan was followed by a boost of 10 Gy to the enhancing tumor with a 2 cm margin along white matter tracts. The combined radiotherapy plan is displayed in Figure 3. The patient was placed on dexamethasone during the course of radiation therapy due to concerns that radiotherapy may potentially worsen local edema which could then result in obstruction of the cerebral aqueduct.

The patient developed alopecia and Common Terminology Criteria for Adverse Events version 4 Grade 1 dermatitis during the course of chemoradiation, but otherwise tolerated his concurrent chemoradiation well. Daily CT scans were used for radiotherapy image guidance and showed no signs of hydrocephalus developing during treatment. An MRI 4 weeks after completion of radiotherapy showed a slight decrease in the size of the pineal GBM to 2.3 cm × 2.0 cm × 1.9 cm. He continued on maintenance

![FIGURE 1](image1.png) Axial (A) and sagittal (B) T1 post-contrast and T2 fluid attenuated inversion recovery (C) images of the tumor at initial presentation.

![FIGURE 2](image2.png) Hematoxylin and eosin stains of the tumor, showing necrosis at 20× (A), mitotic figures at 40× (B), and microvascular proliferation at 40× (C).
therapy with temozolomide, 5 days out of every 28 days per cycle, at 150 mg/m² for the first cycle and increased to 200 mg/m² for subsequent cycles.

An MRI was performed at 58 weeks post-biopsy that showed two new lesions in the brainstem and parietal lobe, both within the prior radiotherapy fields. A total spine MRI did not reveal any drop metastases, nor was there any indication of CSF dissemination per lumbar puncture. Bevacizumab 7.5 mg/kg every 3 weeks was added to the temozolomide therapy (5). Temozolomide was discontinued after 17 cycles, a total of 88 weeks after the biopsy. Due to clinical symptoms of worsening gait disturbance, which corresponded to MRI findings suspicious for infarct within the radiotherapy fields, at 129 weeks post-biopsy, bevacizumab was discontinued and serial MRIs were subsequently performed every 2 months to closely monitor his disease. The MRI performed 146 weeks after the initial biopsy, when compared over multiple prior studies dating back to 111 weeks post-biopsy, showed subtle, progressive increase in size of the pineal mass from 11 mm × 11 mm to 14 mm × 11 mm and a confluent periven-tricular white matter T2/fluid attenuated inversion recovery hyperintensity that is non-specific and stable, this was redemon-strated in his MRI at 166 weeks after biopsy (Figure 4).

Clinically, the patient continues to have double vision, which is corrected by prism glasses. The diplopia continues to cause gait disturbance, which has improved with physical therapy and the patient no longer requires the use of a cane. He was last seen in clinic 166 weeks following his biopsy and 156 weeks following the initiation of chemoradiation for a follow up. He was continuously monitored closely off systemic therapy.

**DISCUSSION**

Tumors of the pineal region are uncommon intracranial neoplasms. The most common glioma in the pineal region is a well-differentiated astrocytoma (1). GBM, though common in the brain as a whole, is rarely seen in the pineal region. Since the first report on primary pineal GBM by Bradfield and Perez in 1972, 24 case reports have been described (6–23) (Table 1).

The clinical symptoms associated with the presentation of a pineal GBM are associated with compression of adjacent structures. Of the 24 cases in the literature, 54.1% have a survival duration of less than 11 months, and 70.8% having a survival duration of less than 24 months. Of the 18 patients where survival was reported (excluding our current patient), the median
<table>
<thead>
<tr>
<th>Reference</th>
<th>Age</th>
<th>Sex</th>
<th>Symptoms</th>
<th>Radiographic findings</th>
<th>Leptomeningeal dissemination</th>
<th>Treatment</th>
<th>Survival</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bradfield et al. (6)</td>
<td>53</td>
<td>F</td>
<td>N/A</td>
<td>HCP, mass in posterior third ventricle</td>
<td>No (autopsy)</td>
<td>Resection</td>
<td>Post-operative death</td>
</tr>
<tr>
<td>Bradfield et al. (6)</td>
<td>5</td>
<td>F</td>
<td>N/A</td>
<td>HCP, mass in posterior third ventricle</td>
<td>No (autopsy)</td>
<td>Shunt</td>
<td>27 months</td>
</tr>
<tr>
<td>DeGirolami et al. (8)</td>
<td>3 cases</td>
<td></td>
<td>Increased ICP, vertical gaze palsy in one</td>
<td>N/A</td>
<td>No/A</td>
<td>RT for all three cases, resection for one</td>
<td>N/A</td>
</tr>
<tr>
<td>Kalyanaraman (12)</td>
<td>68</td>
<td>F</td>
<td>Ataxia, confusion, urinary incontinence, upgaze limitation</td>
<td>CT: HCP, calcified midline mass</td>
<td>N/A</td>
<td>Resection, RT</td>
<td>4 months</td>
</tr>
<tr>
<td>Norbut et al. (13)</td>
<td>36</td>
<td>F</td>
<td>HA, blurry vision, Parinaud's Syndrome</td>
<td>CT: HCP, mass in posterior third ventricle</td>
<td>Yes</td>
<td>Shunt, RT</td>
<td>4 months</td>
</tr>
<tr>
<td>Frank et al. (10)</td>
<td>52</td>
<td>F</td>
<td>Intracranial ICP, oculomotor disturbances</td>
<td>HCP, mass in third ventricle</td>
<td>N/A</td>
<td>Stereotactic biopsy, RT</td>
<td>4 months</td>
</tr>
<tr>
<td>Edwards et al. (9)</td>
<td>12</td>
<td>F</td>
<td>N/A</td>
<td>N/A</td>
<td>No/A</td>
<td>Resection, RT, chemo</td>
<td>18 months</td>
</tr>
<tr>
<td>Vaquero et al. (17)</td>
<td>63</td>
<td>F</td>
<td>HA, behavioral changes</td>
<td>CT: rounded hyperdense, mass with ring enhancement</td>
<td>N/A</td>
<td>Shunt, resection, whole brain RT</td>
<td>6 months</td>
</tr>
<tr>
<td>Pople et al. (14)</td>
<td>6</td>
<td>F</td>
<td>HA, N/V, diplopia, decreased visual acuity, CN VI palsy, upgaze limited</td>
<td>CT and MRI: HCP, enhancing mass</td>
<td>Yes</td>
<td>Shunt, resection, local RT, chemo</td>
<td>4 months</td>
</tr>
<tr>
<td>Cho et al. (7)</td>
<td>63</td>
<td>M</td>
<td>Increased ICP, changing behavior</td>
<td>HCP, hyperdense pineal mass with enhancement</td>
<td>N/A</td>
<td>Resection, RT</td>
<td>6 months</td>
</tr>
<tr>
<td>Gasparetto et al. (11)</td>
<td>29</td>
<td>F</td>
<td>HA, drowsiness, fever, dizziness, seizure</td>
<td>CT and MRI: ill-defined heterogeneously enhanced mass with extension to thalamus</td>
<td>No</td>
<td>Shunt, resection</td>
<td>2 months</td>
</tr>
<tr>
<td>Toyooka et al. (15)</td>
<td>49</td>
<td>M</td>
<td>HA, diplopia, memory disturbance</td>
<td>MRI: HCP, irregular heterogeneously enhanced mass</td>
<td>Yes</td>
<td>Shunt, resection, chemo (ACNU), local RT</td>
<td>11 months</td>
</tr>
<tr>
<td>Amini et al. (16)</td>
<td>40</td>
<td>M</td>
<td>HA, N/V, diplopia, blurry vision</td>
<td>CT: obstructive HCP, strong enhancement, punctuate calcification MRI: heterogeneously enhancing with central necrosis, extension into midbrain</td>
<td>Yes</td>
<td>Endoscopic TVB, resection, shunt, whole brain RT, chemo (temozolomide)</td>
<td>5 months</td>
</tr>
<tr>
<td>Amini et al. (16)</td>
<td>43</td>
<td>M</td>
<td>Ha, disequilibrium, decreased level of mental status</td>
<td>MRI: heterogeneously enhancing, HCP</td>
<td>Yes</td>
<td>TVB, resection, whole brain RT, chemo</td>
<td>7 months</td>
</tr>
<tr>
<td>Amini et al. (16)</td>
<td>52</td>
<td>F</td>
<td>HA, N/V, diplopia, blurry gaze palsy</td>
<td>MRI: heterogeneously enhancing with central necrosis, obstructive HDC</td>
<td>Yes</td>
<td>Endoscopic TVB, RT</td>
<td>2 months</td>
</tr>
<tr>
<td>Moon et al. (20)</td>
<td>68</td>
<td>M</td>
<td>HA, N/V, ataxia</td>
<td>CT: HCP, hypodense mass MRI: irregular heterogeneously ring-enhanced mass with central necrosis</td>
<td>Yes</td>
<td>Resection, shunt</td>
<td>2 months</td>
</tr>
<tr>
<td>Ozgural et al. (18)</td>
<td>60</td>
<td>M</td>
<td>HA, ataxia</td>
<td>CT: triventricular HCP, isodense rounded mass MRI: heterogeneous, contrast enhanced mass</td>
<td>N/A</td>
<td>RT, chemo</td>
<td>24 months</td>
</tr>
<tr>
<td>Mansour et al. (21)</td>
<td>69</td>
<td>M</td>
<td>Altered mental status, vertigo</td>
<td>CT and MRI: heterogeneous mass, HCP</td>
<td>N/A</td>
<td>Biopsy, chemo, RT</td>
<td>16 months</td>
</tr>
<tr>
<td>Suzuki et al. (22)</td>
<td>65</td>
<td>M</td>
<td>Disturbed consciousness</td>
<td>CT: intraventricular hemorrhage, HCP</td>
<td>N/A</td>
<td>Resection, RT, chemo</td>
<td>N/A</td>
</tr>
<tr>
<td>Sugita et al. (23)</td>
<td>52</td>
<td>F</td>
<td>HA, memory disturbance</td>
<td>MRI: mass in pineal, HCP</td>
<td>N/A</td>
<td>Resection, RT, chemo</td>
<td>24 months</td>
</tr>
<tr>
<td>Sugita et al. (23)</td>
<td>18</td>
<td>M</td>
<td>HA, CN VI palsy</td>
<td>MRI: mass in the pineal, HCP</td>
<td>N/A</td>
<td>Resection, RT, chemo</td>
<td>13 months</td>
</tr>
<tr>
<td>Liu et al. (19)</td>
<td>30</td>
<td>M</td>
<td>HA, vomiting, LE numbness</td>
<td>MRI: multifocal lesion largest at the right thalamus</td>
<td>N/A</td>
<td>Resection, RT, chemo</td>
<td>N/A</td>
</tr>
<tr>
<td>Present case</td>
<td>65</td>
<td>M</td>
<td>Right CN IV palsy with gait difficulties</td>
<td>CT: heterogeneous mass</td>
<td>N/A</td>
<td>Biopsy, chemo, RT</td>
<td>&gt;38 months</td>
</tr>
</tbody>
</table>
survival was 6 months (range, 2–24 months). Only one other patient has survived longer than 2 years. The maximum survival documented is the case presented in this report, with a survival time of 38 months at the time of manuscript preparation.

Pineal GBM is generally associated with a poor prognosis. Of the three cases that were treated with radiotherapy alone, the median survival was 3.5 months (range, 0–4 months) (10, 13, 16). The three patients in the literature treated with surgery alone had a median survival of 1.5 months, with a maximum survival of 2 months (6, 11, 20). Patients treated with resection followed by radiotherapy had a slightly higher median survival of 5.5 months (range, 4–6 months) (7, 12, 17). A tri-modal treatment approach of surgical resection followed by chemotherapy and radiotherapy yielded a median survival time of 12 months (range, 4–24 months) among the cases reported thus far in the literature (9, 14–16, 21, 23). However, those patients who received radiotherapy and chemotherapy without resection, including the present case, had the highest median survival duration of 20 months (range, 7–36 months) (16, 18, 21).

It is unknown why patients who did not undergo resection appear to have had a more favorable outcome in this review, indeed the difficulty of achieving a gross total resection in tumors located in this region is thought to be one of the factors that contribute to the poor prognosis of tumors in this region (7, 18, 20, 21), in addition to the propensity for pineal region GBMs to exhibit leptomeningeal spread of disease (13, 16, 21, 24), and the fact that progressive disease in this region could quickly affect critical structures in proximity to the pineal gland (16, 24). It may be possible that any attempt at resection could increase the risk of leptomeningeal seeding, and perhaps coverage of a significant volume of the ventricles in the radiotherapy plan as was done in this patient could aid in sterilizing leptomeningeal disease, but these hypotheses need to be studied in more detail.

O-6-methylguanine-DNA methyltransferase promoter methylation predicts for better outcomes for patients with GBM in other locations in the brain, including patients with an unresectable GBM (24). Our patient’s favorable outcome is likely associated with his MGMT promoter methylation status. To our knowledge, this is the first reported pineal GBM with MGMT promoter methylation. In prior literature, the methylation status was either not reported or was negative. A comparison of survival times of patients treated with chemoradiation based on MGMT promoter status would be valuable once more cases are reported, the results may lend more support to the premise that reasonable survival outcomes can be achieved with chemoradiation in MGMT promoter methylated patients in the absence of gross total resection.

Based on the literature review performed for this report, there is no reported utilization of bevacizumab in patients with pineal region GBM. Our patient had an excellent response to bevacizumab with good long-term control of disease after initial progression, which has contributed to his good overall survival. This favorable response reflects data seen in cases of recurrent GBM outside of the pineal region (5).

CONCLUDING REMARKS

Pineal GBM is a rare disease that is associated with a poor prognosis. The majority of patients present with signs of increased intracranial pressure and visual symptoms. It is difficult to draw conclusions from the small number of total patients reported over a number of decades with differing treatment paradigms. This is the first pineal region GBM that reports positive MGMT promoter methylation and use of bevacizumab upon progression. Our case suggests that durable control of the disease can potentially be achieved in the absence of a gross total surgical resection. Further research in the role of MGMT methylation as a prognostic indicator and of the response of pineal region GBM to bevacizumab is warranted.

ETHICS STATEMENT

The patient described in this case report consented to have his case described in this manuscript. Written permission was obtained from the patient’s treating medical oncologist for publication. The patient’s personal identifiers were not included in this manuscript.

AUTHOR CONTRIBUTIONS

HS: primary author of manuscript. CM: provided comments regarding case pathology with figures. JW: provided comments regarding patient’s systemic therapy and associated toxicities. DR: provided comments regarding patient’s systemic therapy and associated toxicities, provided radiographs. AJ: assisted primary author in manuscript preparation. Provided information regarding patient’s radiotherapy.

FUNDING

This manuscript did not have any sources of funding.

REFERENCES


Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.